Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial
Years of collaboration among Gubra and Boehringer Ingelheim have now entered a new phase after the partnership's first potential drug has entered clinical trials on human subjects.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.